Optinose Debt Financing

Optinose Announces $100 Million Debt Financing from Athyrium Capital Management

YARDLEY, Pa., Jan. 2, 2018 — Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it has entered into a $100 million debt financing agreement with funds managed by Athyrium Capital Management, LP, a leading global healthcare-focused investment firm.

View full press release here